Efficacy and safety of subcutaneous immunotherapy with a mixture of glutaraldehyde-modified extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis

• Published in: The World Allergy Organization journal Vol. 15; no. 9; p. 100692
• Main Authors: Cardona-Villa, Ricardo, Uribe-Garcia, Susana, Calvo-Betancur, Víctor Daniel, Cantillo, Jose Fernando, Fernández-Caldas, Enrique
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2022; World Allergy Organization; Elsevier
• Subjects: Allergic rhino-conjunctivitis; Full-Length; Glutaraldehyde-polymerized extracts; House dust mites; Immunotherapy; Glutaraldehyde-polymerized extracts; House dust mites; Allergic rhino-conjunctivitis; Immunotherapy
• ISSN: 1939-4551; 1939-4551
• DOI: 10.1016/j.waojou.2022.100692

Allergen Immunotherapy (AIT) is an effective treatment of allergic respiratory diseases induced by the inhalation of house dust mite allergens. To evaluate the efficacy and safety of glutaraldehyde polymerized allergen extracts using a mixture of Dermatophagoides pteronyssinus, D. farinae and Blomia tropicalis in mite allergic individuals residing in Colombia. Two hundred and fifty (250) patients with allergic rhinoconjunctivitis with, or without asthma and sensitized to D. pteronyssinus, D. farinae and B. tropicalis were included. A glutaraldehyde-modified extract containing a mixture of D. pteronyssinus, D. farinae and B. tropicalis was employed, using a cluster up-dosing schedule followed by a monthly maintenance dose. The primary endpoints to evaluate the clinical impact were the Combined Symptom and Medication Scores (CSMS) for allergic rhinitis, the Asthma Control Test (ACT) and the reduction in medication consumption. Significant improvement was found after 3 months of treatment regarding CSMS (p < 0.0001) and ACT (p < 0.0001). Additionally, a significant decrease in medication consumption was found after 3 months of treatment (p < 0.0001). Adverse reactions, either local or systemic were mild and no severe reactions related to the vaccines were observed. After 12 months of allergen immunotherapy, glutaraldehyde-modified mixture of D. pteronyssinus, D. farinae and B. tropicalis proved to be safe and effective in the treatment of patients with rhinoconjunctivitis with or without asthma due to allergy to mites.